Eltrombopag vs. rhTPO to Increase Platelet Level After HSCT

• Status: Recruiting
• Trial end date: 2021-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective is to compare the efficacy of eltrombopag vs rhTPO in complete response in patients after HSCT in China. This is a post-marketing, interventional, single-center, double-arm, prospective, open-label, equivalent, randomized controlled study in adult patients with hematopoietic stem cell transplantation in China. Patients will be recruited consecutively from the study sites during the enrollment period. The enrolled patients will be given eltrombopag or rhTPO under the conditions of informed consent and frequent monitoring according to the clinical guideline.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shenzhen Second People's Hospital

Criteria

Inclusion Criteria:

• Age ≥ 18;

• Patients who have undergone hematopoietic stem cell transplantation (HSCT);

• Patients who don't take any drug including Eltrombopag and rhTPO before hematopoietic stem cell transplantation (HSCT);

• Patients receiving either an autologous (Auto) or allogeneic (Allo) stem cell transplantation from a sibling,related donor, or matched unrelated donor are included;

• Agree to sign informed consent

Exclusion Criteria:

• Patients with thrombocytopenia causes by other reasons, such as drugs, cytomegalovirus or infection;

• Patients who had greater risk of thromboembolic disease within six months;

• Patients with a history of heart disease;

• Patients with severe organ dysfunction;

• Patients with other malignancies